Plant-based Biologic Market Size is USD 62.18 Million in 2025
Stats ID: 8630
| Delivery Format: Databook
| Last Updated: August 2025
| Delivery:Immediate
The global plant-based biologic market size surpassed USD 57.36 million in 2024 and is predicted to reach around USD 128.5 million by 2034, registering a CAGR of 8.4% from 2025 to 2034. Driven by critical product segments and diverse end-use applications. The world market for recombinant proteins is growing feverishly because of the burden of chronic disease, expansion of biologics, and technology advances.
Cytokine and growth factors remain the top-selling products. Therapeutic applications continue to lead the overall revenue contribution globally. Rising levels of chronic illness among populations, biosimilar development planned after patent expiries, opportunities in personalized medicine, biotechnology innovations, increasing research and development investments, and government policies that support these areas, are all contributing collectively to the strong expansion and performance of the global recombinant proteins market. The challenges that affect the recombination proteins market are: high production and purification costs, challenges in the regulatory pathways facing new therapies, lack of bio-foundries or production infrastructures in certain emerging nations, alternative therapeutic approaches, and lack of medical need in some markets slow the widespread adoption of recombinant proteins and limit global growth. There are a number of promising growth-enhancing areas within the recombinant proteins space, including CRISPR-Cas9 and AI-based protein design, the growth of CMO and contract research organizations outsourcing services, the segment of biosimilars and bio-betters, as well as applications in diagnostics, regenerative medicine, and agriculture.
In August 2023, Danaher acquired Abcam and expanded its portfolio of recombinant proteins and life science tools. This acquisition further enhances Danaher's research-based applications to lead in recombinant proteins and demonstrates Danaher's focus and commitment to being a market leader in recombinant proteins.
